Telomir Pharmaceuticals Files 8-K
Ticker: TELO · Form: 8-K · Filed: Mar 19, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 8-k, regulatory-filing
TL;DR
Telomir Pharma filed an 8-K on 3/19. Details TBD.
AI Summary
Telomir Pharmaceuticals, Inc. filed an 8-K on March 19, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.
Why It Matters
This filing indicates a material event has occurred for Telomir Pharmaceuticals, but the lack of detail requires further investigation to understand its implications.
Risk Assessment
Risk Level: medium — The filing is an 8-K, which typically reports material events, but the lack of specific information in this filing creates uncertainty.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- March 19, 2025 (date) — Filing Date
FAQ
What specific event(s) are being reported under "Other Events" in this 8-K filing?
The provided text of the 8-K filing does not specify the nature of the "Other Events" being reported.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on March 19, 2025.
What is the principal executive office address for Telomir Pharmaceuticals, Inc.?
The principal executive office is located at 100 SE 2nd St, Suite 2000, #1009, Miami, Florida.
What is the telephone number for Telomir Pharmaceuticals, Inc.?
The telephone number is (786) 396-6723.
What is the SIC code for Telomir Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 19, 2025 regarding Telomir Pharmaceuticals, Inc. (TELO).